These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 19591927)

  • 1. Comparison of dissolution profiles obtained from nifedipine extended release once a day products using different dissolution test apparatuses.
    Garbacz G; Golke B; Wedemeyer RS; Axell M; Söderlind E; Abrahamsson B; Weitschies W
    Eur J Pharm Sci; 2009 Sep; 38(2):147-55. PubMed ID: 19591927
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of two marketed nifedipine modified-release formulations: an exploratory clinical food interaction study.
    Wonnemann M; Schug B; Anschütz M; Brendel E; De Nucci G; Blume H
    Clin Ther; 2008 Jan; 30(1):48-58. PubMed ID: 18343242
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Irregular absorption profiles observed from diclofenac extended release tablets can be predicted using a dissolution test apparatus that mimics in vivo physical stresses.
    Garbacz G; Wedemeyer RS; Nagel S; Giessmann T; Mönnikes H; Wilson CG; Siegmund W; Weitschies W
    Eur J Pharm Biopharm; 2008 Oct; 70(2):421-8. PubMed ID: 18582568
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Controlled release of nifedipine from mucoadhesive tablets of its inclusion complexes with beta-cyclodextrin.
    Chowdary KP; Kamalakara RG
    Pharmazie; 2003 Oct; 58(10):721-4. PubMed ID: 14609284
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Significant food interactions observed with a nifedipine modified-release formulation marketed in the European Union.
    Wonnemann M; Schug B; Schmücker K; Brendel E; van Zwieten PA; Blume H
    Int J Clin Pharmacol Ther; 2006 Jan; 44(1):38-48. PubMed ID: 16425970
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Regulatory aspects of modified release dosage forms: special cases of dissolution testing using the flow-through system.
    Möller H; Wirbitzki E
    Boll Chim Farm; 1993 Apr; 132(4):105-15. PubMed ID: 8333916
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Optimization and characterization of a pH-independent extended-release hydrophilic matrix tablet.
    Timmins P; Delargy AM; Howard JR
    Pharm Dev Technol; 1997 Feb; 2(1):25-31. PubMed ID: 9552428
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dissolution testing of marketed rifampicin containing fixed dose combination formulations using a new discriminative media: a post marketing retrospective study.
    Panchagnula R; Kumar Bajpai A; Agrawal S; Ashokraj Y
    Pharmazie; 2006 Oct; 61(10):851-4. PubMed ID: 17069424
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of food on the pharmacokinetics of nifedipine in two slow release formulations: pronounced lag-time after a high fat breakfast.
    Schug BS; Brendel E; Chantraine E; Wolf D; Martin W; Schall R; Blume HH
    Br J Clin Pharmacol; 2002 Jun; 53(6):582-8. PubMed ID: 12047482
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of novel sustained-release system, disintegration-controlled matrix tablet (DCMT) with solid dispersion granules of nilvadipine (II): in vivo evaluation.
    Tanaka N; Imai K; Okimoto K; Ueda S; Tokunaga Y; Ibuki R; Higaki K; Kimura T
    J Control Release; 2006 May; 112(1):51-6. PubMed ID: 16545477
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of WHO and US FDA biowaiver dissolution test conditions using bioequivalent doxycycline hyclate drug products.
    Strauch S; Jantratid E; Dressman JB
    J Pharm Pharmacol; 2009 Mar; 61(3):331-7. PubMed ID: 19222905
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sandwiched osmotic tablet core for nifedipine controlled delivery.
    Liu L; Khang G; Rhee JM; Lee HB
    Biomed Mater Eng; 1999; 9(5-6):297-310. PubMed ID: 10822485
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of floating and sticking extended release delivery systems: an unconventional dissolution test.
    Dürig T; Fassihi R
    J Control Release; 2000 Jun; 67(1):37-44. PubMed ID: 10773327
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Permeability assessment for solid oral drug formulations based on Caco-2 monolayer in combination with a flow through dissolution cell.
    Motz SA; Schaefer UF; Balbach S; Eichinger T; Lehr CM
    Eur J Pharm Biopharm; 2007 May; 66(2):286-95. PubMed ID: 17156983
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Bioequivalence of nifedipine sustained-release formulations in comparison to standard preparations in solid state].
    Herrmann R
    Arzneimittelforschung; 1996 Jan; 46(1):28-34. PubMed ID: 8821514
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ethanol effects on drug release from Verapamil Meltrex, an innovative melt extruded formulation.
    Roth W; Setnik B; Zietsch M; Burst A; Breitenbach J; Sellers E; Brennan D
    Int J Pharm; 2009 Feb; 368(1-2):72-5. PubMed ID: 18992310
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Application of biorelevant dissolution tests to the prediction of in vivo performance of diclofenac sodium from an oral modified-release pellet dosage form.
    Jantratid E; De Maio V; Ronda E; Mattavelli V; Vertzoni M; Dressman JB
    Eur J Pharm Sci; 2009 Jun; 37(3-4):434-41. PubMed ID: 19491035
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of two dissolution apparatuses: rotating basket versus rotating flask.
    Koch HP; Alcorn G; Ritschel WA
    Pharmazie; 1983 Apr; 38(4):233-5. PubMed ID: 6867085
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development and validation of dissolution tests for fexofenadine hydrochloride capsules and coated tablets.
    Breier AR; Paim CS; Steppe M; Schapoval EE
    J Pharm Pharm Sci; 2005 Aug; 8(2):289-98. PubMed ID: 16124939
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diclofenac sodium multisource prolonged release tablets--a comparative study on the dissolution profiles.
    Bertocchi P; Antoniella E; Valvo L; Alimonti S; Memoli A
    J Pharm Biomed Anal; 2005 Apr; 37(4):679-85. PubMed ID: 15797788
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.